The non-randomized phase 1b KEYNOTE-028 “basket” trial assessed pembrolizumab in a large cohort of patients with advanced solid tumors and positive PD-L1 (≥1% membranous expression in tumor or stromal cells). Here, CD274 is linked to neoplasm.